Bir kamu projesi olarak İnsülin biyobenzerinin geliştirilmesi için G.Kore’de Celltrion seçildi.
Kalem tipi kullanımı olacak üründe cihazı geliştirici firma Tıbbi Cihaz üreticisi Poonglim Pharmatech.
Proje bazında seçilen firmalarla işbirliği ve Devlet tarafından desteklenme modeli Türkiye’de birçok kimse tarafından dile getirilmekte örnek model olarak önerilmektedir.
Celltrion selected for state project to develop pen-type insulin biosimilar
![[Courtesy of Celltrion]](https://image.ajunews.com/content/image/2020/06/03/20200603105738966135.jpg)
SEOUL — Celltrion, a bio firm in South Korea, will develop a pen-type insulin biosimilar. It has yet to decide which products will be used as an original medicine.
Celltrion will be in charge of clinical trials and the development of an insulin biosimilar, while Poonglim Pharmatech, a domestic medical device manufacturer, will develop an automatic free-field pen-type injection. The two companies were selected for a state project supervised by the state-run Korea Evaluation Institute of Industrial Technology (KEIT) to develop customized diagnostic treatment products.
